311 related articles for article (PubMed ID: 22133583)
21. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy.
Jerkeman A; Norkrans G; Lidman C; Westin J; Lagging M; Frimand J; Simonsberg C; Kakko J; Widell A; Björkman P
Eur J Gastroenterol Hepatol; 2014 May; 26(5):523-31. PubMed ID: 24637496
[TBL] [Abstract][Full Text] [Related]
22. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.
Perlman DC; Jordan AE; Uuskula A; Huong DT; Masson CL; Schackman BR; Des Jarlais DC
Int J Drug Policy; 2015 Nov; 26(11):1056-63. PubMed ID: 26050614
[TBL] [Abstract][Full Text] [Related]
23. Exploring stakeholder perceptions of facilitators and barriers to accessing methadone maintenance clinics in Yunnan Province, China.
Philbin MM; Zhang F
AIDS Care; 2010 May; 22(5):623-9. PubMed ID: 20229375
[TBL] [Abstract][Full Text] [Related]
24. Experience with viral hepatitis C treatment among people who inject drugs and participate in a methadone substitution treatment program.
Krekulová L; Vavrinčíková L
Epidemiol Mikrobiol Imunol; 2021; 70(1):18-25. PubMed ID: 33853334
[TBL] [Abstract][Full Text] [Related]
25. DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy.
Radley A; Tait J; Dillon JF
Int J Drug Policy; 2017 Sep; 47():126-136. PubMed ID: 28647161
[TBL] [Abstract][Full Text] [Related]
26. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P
Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S39-45. PubMed ID: 23884064
[TBL] [Abstract][Full Text] [Related]
27. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study.
Treloar C; Rance J; Dore GJ; Grebely J;
J Viral Hepat; 2014 Aug; 21(8):560-7. PubMed ID: 24299222
[TBL] [Abstract][Full Text] [Related]
28.
Byrne C; Radley A; Inglis SK; Beer LJZ; Palmer N; Pham MD; Healy B; Doyle JS; Donnan P; Dillon JF
BMJ Open; 2020 Aug; 10(8):e036501. PubMed ID: 32868356
[TBL] [Abstract][Full Text] [Related]
29. Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study.
Gunn J; Higgs P
Res Social Adm Pharm; 2020 Sep; 16(9):1298-1301. PubMed ID: 31003763
[TBL] [Abstract][Full Text] [Related]
30. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study.
Litwin AH; Drolet M; Nwankwo C; Torrens M; Kastelic A; Walcher S; Somaini L; Mulvihill E; Ertl J; Grebely J
J Viral Hepat; 2019 Sep; 26(9):1094-1104. PubMed ID: 31074167
[TBL] [Abstract][Full Text] [Related]
31. Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration.
Larney S; Toson B; Burns L; Dolan K
Addiction; 2012 Feb; 107(2):372-80. PubMed ID: 21851442
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis C Virus Prevalence and Incidence in a Large Nationwide Sample of Patients in Opioid Substitution Treatment in Germany: A Prospective Cohort Study.
Schulte B; Schmidt CS; Strada L; Rosenkranz M; Schäfer I; Verthein U; Reimer J
Clin Infect Dis; 2020 May; 70(10):2199-2205. PubMed ID: 31631215
[TBL] [Abstract][Full Text] [Related]
33. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.
Doab A; Treloar C; Dore GJ
Clin Infect Dis; 2005 Apr; 40 Suppl 5():S313-20. PubMed ID: 15768340
[TBL] [Abstract][Full Text] [Related]
34. Knowledge of and interest in hepatitis C treatment at a methadone clinic.
Walley AY; White MC; Kushel MB; Song YS; Tulsky JP
J Subst Abuse Treat; 2005 Mar; 28(2):181-7. PubMed ID: 15780548
[TBL] [Abstract][Full Text] [Related]
35. A model for treating HCV hepatitis in patients receiving methadone maintenance therapy.
Malnick S; Sheidvasser V; Basevitz A; Levit S
Isr J Psychiatry Relat Sci; 2014; 51(4):303-5. PubMed ID: 25841229
[TBL] [Abstract][Full Text] [Related]
36. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment.
Watson B; Conigrave KM; Wallace C; Whitfield JB; Wurst F; Haber PS
Drug Alcohol Rev; 2007 May; 26(3):231-9. PubMed ID: 17454012
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of Iranian women seeking drug treatment.
Dolan K; Salimi S; Nassirimanesh B; Mohsenifar S; Allsop D; Mokri A
J Womens Health (Larchmt); 2011 Nov; 20(11):1687-91. PubMed ID: 21905877
[TBL] [Abstract][Full Text] [Related]
38. Opiate substitution treatment to reduce in-prison drug injection: a natural experiment.
Kinner SA; Moore E; Spittal MJ; Indig D
Int J Drug Policy; 2013 Sep; 24(5):460-3. PubMed ID: 23465644
[TBL] [Abstract][Full Text] [Related]
39. Factors influencing pharmacy services in opioid substitution treatment.
Chaar BB; Wang H; Day CA; Hanrahan JR; Winstock AR; Fois R
Drug Alcohol Rev; 2013 Jul; 32(4):426-34. PubMed ID: 23442133
[TBL] [Abstract][Full Text] [Related]
40. Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care.
Fragomeli V; Weltman M
J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 2():6-11. PubMed ID: 25641224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
